RaQualia Pharma Inc

RaQualia Pharma Inc maintains a strong liquidity position, with a current ratio of 4.46, indicating the company can cover its short-term liabilities more than four times over. The company's liquidity_fpt score is high, supported by cash and equivalents of ¥3.24 billion, which exceeds its total liabilities of ¥3.62 billion. However, the company reported negative operating cash flow of ¥354.4 million, suggesting operational cash generation is not yet robust. Profitability metrics show a return on equity (ROE) of 3.96% and a return on assets (ROA) of 2.6%, both below the median for the Pharmaceuticals industry. This indicates that the company is not currently generating returns at a level typical for its sector. The company's gross profit margin is 82.1%, which is strong, but its operating margin of 12.8% is lower than the industry median, suggesting higher operating costs relative to peers. The company's revenue is concentrated in Japan, with no disclosed international revenue segments. This geographic concentration increases exposure to local regulatory and economic conditions. The company operates in a single business segment focused on drug discovery and licensing, with no material diversification across therapeutic areas or product lines. Revenue growth has been modest, with the most recent reported revenue of ¥3.98 billion. The outlook for the current fiscal year suggests a slight increase in revenue, but the company has not disclosed specific growth targets or drivers. The company's capital expenditures are minimal, with a negative value of ¥74.7 million, indicating a focus on cost control and asset preservation. The company's risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The debt-to-equity ratio of 0.42 is below the industry median, suggesting a conservative capital structure. The company has not issued new shares recently, and there are no indications of near-term dilution pressure. Recent events include the disclosure of financial results showing a net income of ¥273.1 million and a total equity of ¥6.90 billion. The company has not disclosed any major new product launches or licensing agreements in the latest filings.